PHILADELPHIA, May 13, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced the addition of Premier, Inc. (NASDAQ: PINC) to HealthVerity Marketplace™, meaning life sciences organizations using HealthVerity Marketplace™ can now access Premier's high-quality, healthcare data to support research across the product lifecycle.
HealthVerity Marketplace is the nation's largest verified healthcare and consumer data ecosystem, offering access to over 340 million de-identified individuals and enabling precise patient journey insights through the HIPAA-compliant linkage of diverse data types. With the addition of Premier data, HealthVerity Marketplace users can now use the platform to discover and license inpatient and outpatient data that supports evidence generation across a wide range of use cases, including market access, clinical development, and epidemiological research.
Premier data available through HealthVerity Marketplace includes inpatient and outpatient electronic medical record (EMR) data. This opens pathways for the inclusion of de-identified, unstructured clinical notes. These enhancements will enable researchers to further validate clinical insights and strengthen study design with previously unavailable data.
The Premier® Healthcare Database (PHD) is one of the most comprehensive electronic healthcare data repositories and the largest inpatient and outpatient chargemaster database. For nearly 25 years, it has served as a valuable source of RWD for the pharmaceutical and medical device industries, academic institutions, government agencies, and hospitals and health systems. Researchers using the PHD can analyze device and drug utilization with greater specificity, uncover trends in resource use and outcomes, and generate insights into care quality, safety and cost. Premier also offers EMR chart retrieval and review services that support regulatory-grade research and verification needs.
"Our sharp focus on differentiated data, leading-edge research and clinical trials innovation helps drive speed to value," said Denise Juliano, Premier Applied Sciences Group Vice President. "Having the right data is critical for life sciences organizations aspiring to create meaningful change in healthcare.
"Premier's partnership with HealthVerity securely links Premier® data with other real-world datasets, expanding on its longitudinal view of the patient journey that helps measure the effectiveness, quality and cost of therapies."
"We are thrilled to officially welcome Premier as a named partner in HealthVerity Marketplace," said Andrew Kress, CEO of HealthVerity. "Premier's extensive, high-quality data adds substantial value for pharmaceutical manufacturers and healthcare innovators. These precise clinical insights are essential for therapeutic advancements and targeted patient care strategies."
About HealthVerity
HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. To learn more, please visit www.healthverity.com.
HealthVerity contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers, payers and policymakers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, consulting and other services in service of our mission to improve the health of communities. Please visit Premier's news and investor sites on www.premierinc.com; as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier's blog for more information about the company.
Premier contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$23.00 |
Daily Change: | -0.02 -0.09 |
Daily Volume: | 607,961 |
Market Cap: | US$2.210B |
February 04, 2025 December 03, 2024 November 05, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load